Affimed erhält 15,5 Mio. Euro in Series D Finanzierungsrunde

Affimed Therapeutics AG, the therapeutic TandAb antibody company, today announced the successful closing of a Series D financing round of € 15.5 million. The proceeds from this transaction will be used to fund the clinical development of Affimed’s therapeutic pipeline that consists of two TandAb products, AFM11 and AFM13. AFM13, a CD30/CD16A TandAb is currently being evaluated in a phase I clinical trial for the treatment of Hodgkin’s Lymphoma. The results of the trial are expected by December 2012. AFM11 a CD19/CD3 TandAb is in the late stage preclinical development and it is expected to enter phase I clinical studies in 2013. Both candidates have unique properties as shown in preclinical studies… vollständiger Artikel